Clinical Trials

The purpose of this study is to determine the optimal approach to the diagnosis and treatment of patients with thyroid disorders.

We want to determine the efficacy and safety, and the rate and type of side effects of this technique; as well as to delineate the clinical pathologic outcomes of the patients with thyroid cysts treated with Percutaneous ethanol injection (PEI) at Mayo Clinic, Rochester MN, since there is limited information of the use of this technique in the American literature.

The purpose of this study is to measure the impact of thyroid ablation on patient’s thyroid-related symptoms using a pre-existing scoring system. 

The primary objective is to characterize the immune cell phenotypes in thyroid fine needle aspirates (FNA) and the peripheral blood of patients with ICI-induced thyroid dysfunction using flow cytometry. Control patients will be those with thyroid nodules as well as autoimmune thyroid disease, with and without exposure to ICI.

The purpose of this study is to determine the placental D3 activity in a woman with RTH and compare to women without RTH because we believe this may be a potential mechanism which limits fetal thyroid hormone exposure.

The purpose of this study is to evaluate the safety, effectiveness and need for re-treatment of 3 different teprotumumab treatment durations for thyroid eye disease (TED). In addition, serum samples from patients with a Baseline Clinical Activity Score (CAS) ≥ 3 will be evaluated for biomarkers of disease.

Teprotumumab was approved by the United States Food and Drug Administration on 21 January 2020 for the treatment of TED under the name TEPEZZA® (teprotumumab-trbw). 

The investigators' decision aid for patients with GD, GD Choice, will be the result of a user-centered participatory action research involving) synthesis of the best available evidence from the literature and real-world registry experience, ii) input and involvement of patients, clinicians and other stakeholders, iii) direct observation of encounters and iv) extensive field-testing. The goal is to create a decision aid that will be rigorously evidence-based, clear and complete, able to be used by clinicians with minimal training time, while satisfying extant standards for rigorous high-quality shared decision making tools.

The primary purpose of this study is to investigate the effectiveness, safety and tolerability of TEPEZZA® (teprotumumab-trbw) in comparison to placebo in treating patients with chronic (inactive) TED.

This study is being conducted to characterize the effects of twice daily administration of rhPTH(1-84) on the way the body handles rhPTH(1-84) as well as its actions and safety and tolerability over the course of 24 hours as compared with the current once daily dosing regimen of marketed rhPTH(1-84) (marketed in the United States as Natpara®).

The purpose of this study is to analyze and report orbital decompression outcomes in patients with a thyroid eye disease diagnosis.

The objective is to show that balanced orbital decompression will reduce preoperative Hertel’s measurement when compared to measurements done intraoperatively and remain stable at three-month follow-up. Additionally, to see increased patient satisfaction and quality of life regarding cosmesis when comparing pre and postoperative satisfaction surveys.

The purpose of this study is to develop and evaluate a treatment decision aid for patients with asymptomatic primary hyperparathyroidism.

The purpose of this study is to evaluate the safety and tolerability of linsitinib. Study drug is administered twice daily for six-months (24 weeks) in approximately 75 men and women (25 of which will be randomized to placebo) with active, moderate-to-severe Thyroid Eye Disease (TED).
 

The purpose of this study is to evaluate the patients’ knowledge regarding the risks and benefits of parathyroidectomy in the setting of mild primary hyperparathyroidism.

The purpose of this study is to perform a comprehensive immunophenotypic analysis of peripheral bloods samples from patients with benign and malignant thyroid disease. This data will be used to determine whether patients with advanced thyroid cancers have significantly altered numbers and/or subtypes of circulating immune cells, in particular immunosuppressive monocytes.

The purpose of this study is to establish a human biobank of thyroid-derived tissues and blood samples from patients with thyroid disorders at Mayo Clinic in Rochester.

The study will try to answer the question of whether early treatment with levothyroxine at 4 weeks after radioactive iodine for Graves' disease will prevent overt hypothyroidism (low thyroid hormone levels).

We plan to create a databank of serum and tissue samples from patients with thyroid autoimmunity, mainly focusing on Graves’ disease and Graves’ orbitopathy, respectively. This set of samples will allow us to study these disorders better in the laboratory as well as test potential agents that can be used as therapies.

GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to collect biological samples from donors with a new diagnosis of cancer (blood and tumor tissue) and from donors who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer subjects and to develop models for distinguishing cancer from non-cancer.

The purpose of this study is to evaluate the challenges, behavioral patterns, and preferences of minority patient participation in clinical trials. Also, to develop and validate a personalized clinical trial educational platform to boost participation among underserved cancer patients.